Thirdly, in the development of anti-CD47 bsAbs, another challenge arises from the widespread expression of CD47 on normal tissues, leading to an "antigen sink" effect that hinders the effective binding of therapeutic antibodies with targeted tumor cells in vivo. Here, CD47 is linked to neoplasm.